Posttherapeutic biomarker expression in mCRC patients with liver metastasis”The PRO-MARKER observational study
Recruiting
- Conditions
- C19C78Malignant neoplasm of rectosigmoid junctionSecondary malignant neoplasm of respiratory and digestive organs
- Registration Number
- DRKS00030593
- Lead Sponsor
- MU München
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
• Histologically proven mCRC
• Patients with liver dominant metastatic CRC
• Inclusion after full resection or local ablation of liver metastases
• ECOG 0-2
• Limited extrahepatic metastases
Exclusion Criteria
• Life expectancy =3 months
• Known liver cirrhosis
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Biomarker development (ctDNA) after local therapy or locoregional therapy regimen.
- Secondary Outcome Measures
Name Time Method Progression free survival as determined by HBI MRI of the liver and CT Thorax & Abdomen